Gesynta Pharma: Series B Funding Reaches SEK 347M with New Backers

Gesynta Pharma AB, a Swedish clinical-stage pharmaceutical company, has secured an additional SEK 43 million in a second closing of its Series B funding round, bringing the total to SEK 347 million. HealthCap and Hadean Growth Fund are new investors joining the round alongside lead investor Innovestor Life Science. The funds will support Gesynta's development of vipoglanstat, a novel treatment for endometriosis, a condition affecting 190 million women worldwide. Vipoglanstat is a non-hormonal, non-opioid drug candidate that has shown promising preclinical results. The Series B funding will facilitate the progression of a Phase 2 clinical trial and preparation for a future Phase 3 program. Gesynta also announced the appointment of three new directors to its board. This development underscores a significant strategic push within women's health and the pharmaceutical sector.